- Home
- VUZI vs IMMP Comparison
VUZI vs IMMP Comparison
Compare VUZI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VUZI
- IMMP
- Stock Information
- Founded
- VUZI 1997
- IMMP 1987
- Country
- VUZI United States
- IMMP Australia
- Employees
- VUZI N/A
- IMMP N/A
- Industry
- VUZI Industrial Machinery/Components
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- VUZI Technology
- IMMP Health Care
- Exchange
- VUZI Nasdaq
- IMMP Nasdaq
- Market Cap
- VUZI 207.4M
- IMMP 244.5M
- IPO Year
- VUZI N/A
- IMMP N/A
- Fundamental
- Price
- VUZI $2.41
- IMMP $1.65
- Analyst Decision
- VUZI Strong Buy
- IMMP Buy
- Analyst Count
- VUZI 1
- IMMP 1
- Target Price
- VUZI $2.00
- IMMP $7.00
- AVG Volume (30 Days)
- VUZI 1.8M
- IMMP 87.0K
- Earning Date
- VUZI 08-13-2025
- IMMP 02-27-2025
- Dividend Yield
- VUZI N/A
- IMMP N/A
- EPS Growth
- VUZI N/A
- IMMP N/A
- EPS
- VUZI N/A
- IMMP N/A
- Revenue
- VUZI $5,331,630.00
- IMMP $3,019,249.00
- Revenue This Year
- VUZI $45.35
- IMMP $50.37
- Revenue Next Year
- VUZI $54.01
- IMMP N/A
- P/E Ratio
- VUZI N/A
- IMMP N/A
- Revenue Growth
- VUZI N/A
- IMMP 24.11
- 52 Week Low
- VUZI $0.83
- IMMP $1.32
- 52 Week High
- VUZI $5.79
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- VUZI 42.16
- IMMP 46.73
- Support Level
- VUZI $2.35
- IMMP $1.64
- Resistance Level
- VUZI $3.16
- IMMP $1.74
- Average True Range (ATR)
- VUZI 0.16
- IMMP 0.06
- MACD
- VUZI -0.05
- IMMP 0.01
- Stochastic Oscillator
- VUZI 18.64
- IMMP 66.67
About VUZI Vuzix Corporation
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.